A Four-Arm Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of 3 Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS) Over a 36 Week Treatment Course

Trial Profile

A Four-Arm Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of 3 Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS) Over a 36 Week Treatment Course

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Atacicept (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Acronyms ATAMS
  • Sponsors EMD Serono
  • Most Recent Events

    • 09 Jun 2012 Planned number of patients changed from 250 to 332 as reported by European Clinical Trials Database (Parent trial: EudraCT2007-003936-50).
    • 09 Jun 2012 Official Title amended as reported by European Clinical Trials Database (Parent trial: EudraCT2007-003936-50).
    • 22 Oct 2011 Results presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top